GlassScriptPhysician profile
Beth M Winkler
NPI 1477620417
$9,312.57
in general payments reported to CMS, 2019-2025
45 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $501 · 2021: $1,234 · 2022: $1,149 · 2023: $1,605 · 2024: $1,741 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,402 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.96 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,448.06 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,322.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $897.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $729.46 | 2019-2025 | Vraylar, Viberzi, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.68 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $630.79 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $542.26 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $501.42 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $432.90 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $258.34 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Currax Pharmaceuticals LLC | $223.43 | 2021-2025 | Contrave, Onzetra Xsail, Nexletol |
| Phathom Pharmaceuticals, INC. | $184.15 | 2024-2025 | Voquezna |
| Cranial Technologies, INC | $155.00 | 2021-2025 | Doc Band |
| Idorsia Pharmaceuticals US INC | $133.86 | 2022-2024 | Quviviq |
| Abbott Laboratories | $133.04 | 2021-2025 | Freestyle Libre 3 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Winkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.